Milestone Pharmaceuticals (NASDAQ:MIST) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Milestone Pharmaceuticals (NASDAQ:MISTFree Report) in a research note published on Monday,Benzinga reports. HC Wainwright currently has a $25.00 target price on the stock.

Milestone Pharmaceuticals Stock Down 1.5 %

Shares of NASDAQ:MIST opened at $2.02 on Monday. Milestone Pharmaceuticals has a 1-year low of $1.12 and a 1-year high of $2.75. The company’s fifty day moving average is $1.96 and its two-hundred day moving average is $1.66. The company has a debt-to-equity ratio of 2.18, a quick ratio of 15.40 and a current ratio of 15.40. The stock has a market capitalization of $107.73 million, a price-to-earnings ratio of -2.49 and a beta of 1.78.

Milestone Pharmaceuticals (NASDAQ:MISTGet Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04. Equities analysts anticipate that Milestone Pharmaceuticals will post -0.62 EPS for the current year.

Hedge Funds Weigh In On Milestone Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Valeo Financial Advisors LLC lifted its position in Milestone Pharmaceuticals by 100.0% in the 3rd quarter. Valeo Financial Advisors LLC now owns 20,000 shares of the company’s stock valued at $30,000 after purchasing an additional 10,000 shares during the last quarter. PVG Asset Management Corp acquired a new position in shares of Milestone Pharmaceuticals during the third quarter worth approximately $46,000. Atria Investments Inc increased its position in Milestone Pharmaceuticals by 44.4% in the 3rd quarter. Atria Investments Inc now owns 40,421 shares of the company’s stock valued at $61,000 after acquiring an additional 12,430 shares during the period. Finally, BML Capital Management LLC raised its stake in Milestone Pharmaceuticals by 3.0% during the 3rd quarter. BML Capital Management LLC now owns 1,136,091 shares of the company’s stock valued at $1,727,000 after acquiring an additional 33,196 shares in the last quarter. Institutional investors and hedge funds own 86.18% of the company’s stock.

About Milestone Pharmaceuticals

(Get Free Report)

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.

Further Reading

Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.